Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Substandard and falsified ivermectin tablets obtained for self‐medication during the COVID‐19 pandemic as a source of potential harm

Vanhee et al., Drug Testing and Analysis, doi:10.1002/dta.3618
Dec 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
Analysis of intercepted ivermectin tablets in Belgium showing 100% of 19 samples were either underdosed or severely contaminated with bacteria.
Vanhee et al., 3 Dec 2023, peer-reviewed, 9 authors.
This PaperIvermectinAll
{ 'indexed': {'date-parts': [[2023, 12, 4]], 'date-time': '2023-12-04T05:14:44Z', 'timestamp': 1701666884608}, 'reference-count': 78, 'publisher': 'Wiley', 'license': [ { 'start': { 'date-parts': [[2023, 12, 3]], 'date-time': '2023-12-03T00:00:00Z', 'timestamp': 1701561600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'content-domain': { 'domain': ['analyticalsciencejournals.onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>In 2019, a global viral pandemic, due to the ' 'SARS‐CoV‐2 virus, broke out. Soon after, the search for a vaccine and/or antiviral medicine ' 'began. One of the candidate antiviral medicines tested was ivermectin. Although several ' 'health authorities warned the public against the use of this medicine outside clinical ' 'trials, the drug was widely used at the end of 2020 and in 2021. Simultaneously, several ' 'reports started to emerge demonstrating serious adverse effects after self‐medicating with ' 'ivermectin. It stands to reason that the self‐administration of substandard or falsified (SF) ' 'medicines bearing harmful quality deficiencies have contributed to this phenomenon. In order ' 'to have a better view on the nature of these harmful quality deficiencies, SF ivermectin ' 'samples, intercepted in large quantities by the Belgian regulatory agencies during the period ' '2021–2022, were analyzed in our official medicines control laboratory. None of the samples ' '(<jats:italic>n</jats:italic>\u2009=\u200919) were compliant to the quality criteria ' 'applicable to medicinal products. These SF products either suffered from a systematic ' 'underdosing of the active pharmaceutical ingredient or were severely contaminated with ' 'bacteria, two of which were contaminated with known pathogens that cause gastrointestinal ' 'illness upon oral intake. In addition to the direct risks of self‐medicating with such a ' 'product, the improper usage and dosage of ivermectin medication might also facilitate ' 'ivermectin tolerance or resistance in parasites. This may have detrimental consequences on a ' 'global scale, certainly as the number of newly developed active pharmaceutical ingredients ' 'that can safely be used to combat parasites is rather scarce.</jats:p>', 'DOI': '10.1002/dta.3618', 'type': 'journal-article', 'created': {'date-parts': [[2023, 12, 4]], 'date-time': '2023-12-04T02:11:26Z', 'timestamp': 1701655886000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Substandard and falsified ivermectin tablets obtained for self‐medication during the COVID‐19 ' 'pandemic as a source of potential harm', 'prefix': '10.1002', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6634-3706', 'authenticated-orcid': False, 'given': 'Celine', 'family': 'Vanhee', 'sequence': 'first', 'affiliation': [ { 'name': 'Service Medicines and Health Products, Scientific Direction of ' 'Chemical and Physical Health Risks Sciensano Brussels ' 'Belgium'}]}, { 'ORCID': 'http://orcid.org/0000-0001-7307-9619', 'authenticated-orcid': False, 'given': 'Bram', 'family': 'Jacobs', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service of Foodborne Pathogen, Scientific Direction of ' 'Infectious Diseases in Humans Sciensano Brussels Belgium'}]}, { 'given': 'Angélique', 'family': 'Kamugisha', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service Medicines and Health Products, Scientific Direction of ' 'Chemical and Physical Health Risks Sciensano Brussels ' 'Belgium'}]}, { 'given': 'Michael', 'family': 'Canfyn', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service Medicines and Health Products, Scientific Direction of ' 'Chemical and Physical Health Risks Sciensano Brussels ' 'Belgium'}]}, { 'given': 'Hans', 'family': 'Van Der Meersch', 'sequence': 'additional', 'affiliation': [ { 'name': 'Federal Agency for Medicine and Health Care Products Brussels ' 'Belgium'}]}, { 'given': 'Bart', 'family': 'Ceyssens', 'sequence': 'additional', 'affiliation': [ { 'name': 'Federal Agency for Medicine and Health Care Products Brussels ' 'Belgium'}]}, { 'given': 'Eric', 'family': 'Deconinck', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service Medicines and Health Products, Scientific Direction of ' 'Chemical and Physical Health Risks Sciensano Brussels ' 'Belgium'}]}, { 'given': 'Koenraad', 'family': 'Van Hoorde', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service of Foodborne Pathogen, Scientific Direction of ' 'Infectious Diseases in Humans Sciensano Brussels Belgium'}]}, { 'given': 'Marie', 'family': 'Willocx', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service Medicines and Health Products, Scientific Direction of ' 'Chemical and Physical Health Risks Sciensano Brussels ' 'Belgium'}]}], 'member': '311', 'published-online': {'date-parts': [[2023, 12, 3]]}, 'reference': [ {'key': 'e_1_2_5_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.46234/ccdcw2020.017'}, {'key': 'e_1_2_5_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001017'}, { 'key': 'e_1_2_5_4_1', 'unstructured': 'World Health Organization. Coronavirus disease (COVID‐19) pandemic 2023. ' 'Accessed September 19 ' '2023.https://www.who.int/europe/emergencies/situations/covid-19'}, { 'key': 'e_1_2_5_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2012.06.008'}, {'key': 'e_1_2_5_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1042/BJ20120150'}, { 'key': 'e_1_2_5_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.10.004'}, {'key': 'e_1_2_5_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep23138'}, {'key': 'e_1_2_5_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ceb.2019.01.001'}, {'key': 'e_1_2_5_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pt.2017.02.004'}, { 'key': 'e_1_2_5_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104787'}, { 'key': 'e_1_2_5_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104805'}, {'key': 'e_1_2_5_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12879‐022‐0'}, { 'key': 'e_1_2_5_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/antibiotics11040445'}, {'key': 'e_1_2_5_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2114907'}, { 'key': 'e_1_2_5_16_1', 'unstructured': 'United States Food and Drug Administration Ivermectin intended for ' 'animals: letter to stakeholders—do not use in humans as a treatment for ' 'COVID‐19 2020. Accessed September 19 ' '2023.https://www.fda.gov/safety/medical‐product‐safety‐information/ivermectin‐intended‐animals‐letter‐stakeholders‐do‐not‐use‐humans‐treatment‐covid‐19'}, { 'key': 'e_1_2_5_17_1', 'unstructured': 'Centers of Disease Control Rapid increase in ivermectin prescriptions ' 'and reports of severe illness associated with use of products containing ' 'ivermectin to prevent or treat COVID‐19 2021. Accessed September 19 ' '2023.https://emergency.cdc.gov/han/2021/pdf/CDC_HAN_449.pdf'}, {'key': 'e_1_2_5_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cmi.2022.03.022'}, { 'key': 'e_1_2_5_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.therap.2022.03.002'}, {'key': 'e_1_2_5_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijerph18147475'}, { 'key': 'e_1_2_5_21_1', 'unstructured': 'Swiss medic Illegal imports 2021: Swissmedic seizes significantly more ' 'packages than in 2020.2022. Accessed September 19 ' '2023.https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/statistical-data/importe-illegaler-am-2021.html'}, {'key': 'e_1_2_5_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40278‐022‐07672‐3'}, { 'key': 'e_1_2_5_23_1', 'unstructured': 'World Health Organization WHO global surveillance and monitoring system ' 'for substandard and falsified medical products. World Health ' 'Organization.2017. Accessed September 19 ' '2023.https://apps.who.int/iris/handle/10665/326708'}, {'key': 'e_1_2_5_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1787/a7c7e054‐en'}, {'key': 'e_1_2_5_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4269/ajtmh.14‐0539'}, {'key': 'e_1_2_5_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmjgh‐2017‐000409'}, {'key': 'e_1_2_5_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc0807678'}, { 'key': 'e_1_2_5_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1742‐1241.2009.02328.x'}, {'key': 'e_1_2_5_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jpba.2013.03.023'}, {'key': 'e_1_2_5_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/2050‐6511‐15‐34'}, {'key': 'e_1_2_5_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/dta.2740'}, {'key': 'e_1_2_5_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/forensicsci3030031'}, { 'key': 'e_1_2_5_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.talanta.2018.10.078'}, { 'key': 'e_1_2_5_34_1', 'unstructured': 'International Conference on Harmonisation (ICH) of technical ' 'requirements for registration of pharmaceuticals for human ' 'use—validation of analytical procedures. Accessed 30/05/2023. Available ' 'online:https://database.ich.org/sites/default/files/Q2(R1)Guideline.pdf'}, { 'key': 'e_1_2_5_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chroma.2007.02.021'}, {'key': 'e_1_2_5_36_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00769‐005‐0081‐9'}, { 'key': 'e_1_2_5_37_1', 'unstructured': 'ISO/IEC 17025.General requirements for the competence of testing and ' 'calibration laboratories.2005.'}, { 'key': 'e_1_2_5_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/separations10080444'}, {'key': 'e_1_2_5_39_1', 'volume-title': 'United States Pharmacopoeia 42', 'year': '2022'}, {'key': 'e_1_2_5_40_1', 'volume-title': 'European Pharmacopoeia 10.0', 'year': '2022'}, {'key': 'e_1_2_5_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1471‐2105‐11‐595'}, {'key': 'e_1_2_5_42_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fmicb.2020.580691'}, {'key': 'e_1_2_5_43_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fmicb.2023.1173594'}, {'key': 'e_1_2_5_44_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.02412‐14'}, {'key': 'e_1_2_5_45_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jps.2600811008'}, { 'key': 'e_1_2_5_46_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1365‐2125.2009.03394.x'}, { 'key': 'e_1_2_5_47_1', 'unstructured': 'International Conference on Harmonisation (ICH) of technical ' 'requirements for the registration of pharmaceuticals for human use Q3C ' '(R8): impurities: guidelines for residual solvents Step 42021. Accessed ' 'September 19 ' '2023.https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf'}, {'key': 'e_1_2_5_48_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1099/ijsem.0.003775'}, { 'key': 'e_1_2_5_49_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/microbiolspec.GPP3‐0032‐0018'}, {'key': 'e_1_2_5_50_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JCM.00881‐06'}, {'key': 'e_1_2_5_51_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12866‐019‐1632‐2'}, {'key': 'e_1_2_5_52_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fmicb.2020.599524'}, {'key': 'e_1_2_5_53_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/foods11162480'}, { 'key': 'e_1_2_5_54_1', 'doi-asserted-by': 'publisher', 'DOI': '10.14309/01.ajg.0000785384.55403.41'}, { 'key': 'e_1_2_5_55_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1046/j.1365‐2958.2000.02147.x'}, { 'key': 'e_1_2_5_56_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JCM.43.8.4277‐4279.2005'}, {'key': 'e_1_2_5_57_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JCM.05129‐11'}, {'key': 'e_1_2_5_58_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bcr‐2020‐238716'}, {'key': 'e_1_2_5_59_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4315/0362‐028x‐68.3.636'}, {'key': 'e_1_2_5_60_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/toxins12110701'}, { 'key': 'e_1_2_5_61_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4315/0362‐028X.JFP‐11‐481'}, {'key': 'e_1_2_5_62_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/CMR.00073‐09'}, { 'key': 'e_1_2_5_63_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0041‐008x(69)90058‐1'}, { 'key': 'e_1_2_5_64_1', 'unstructured': 'United States Food and Drug Administration Leaflet Stromectol® ' 'tablets.2009. Accessed September 23 ' '2023.https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf'}, {'key': 'e_1_2_5_65_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4269/ajtmh.17‐0042'}, {'key': 'e_1_2_5_66_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.42603'}, { 'key': 'e_1_2_5_67_1', 'unstructured': 'European commission.The falsified medicines directive 2011/62/EU.2011. ' 'Accessed September 19 ' '2023.https://health.ec.europa.eu/system/files/2016-11/dir_2011_62_en_0.pdf'}, { 'key': 'e_1_2_5_68_1', 'unstructured': 'European commission.EU logo for online sale of medicines.2017. Accessed ' 'September 19 ' '2023.https://health.ec.europa.eu/system/files/2016-11/logosancointernet_charte_v2_0.pdf'}, {'key': 'e_1_2_5_69_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bcp.12298'}, { 'key': 'e_1_2_5_70_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1586/14787210.2015.1015990'}, {'key': 'e_1_2_5_71_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/ja.2017.11'}, {'key': 'e_1_2_5_72_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jpha.2014.03.002'}, {'key': 'e_1_2_5_73_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/dta.2690'}, {'key': 'e_1_2_5_74_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s40360‐021‐00478‐x'}, {'key': 'e_1_2_5_75_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1155/2017/5163968'}, {'key': 'e_1_2_5_76_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2147/IDR.S332378'}, { 'key': 'e_1_2_5_77_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.vprsr.2023.100907.223'}, {'key': 'e_1_2_5_78_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/bjd/ljad308'}, {'key': 'e_1_2_5_79_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pt.2020.09.004'}], 'container-title': 'Drug Testing and Analysis', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2023, 12, 4]], 'date-time': '2023-12-04T02:11:36Z', 'timestamp': 1701655896000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3618'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 12, 3]]}, 'references-count': 78, 'alternative-id': ['10.1002/dta.3618'], 'URL': 'http://dx.doi.org/10.1002/dta.3618', 'relation': {}, 'ISSN': ['1942-7603', '1942-7611'], 'subject': ['Spectroscopy', 'Pharmaceutical Science', 'Environmental Chemistry', 'Analytical Chemistry'], 'container-title-short': 'Drug Testing and Analysis', 'published': {'date-parts': [[2023, 12, 3]]}, 'assertion': [ { 'value': '2023-10-11', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-11-10', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-12-03', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit